BioCentury | Apr 9, 2020
Product Development

AZ’s Pangalos: what the pharma brings to COVID-19 fight, and where it turns to others

In a conversation with BioCentury, AstraZeneca’s Menelas Pangalos highlighted the technologies the pharma thinks could be difference-makers in the pandemic, and the external resources required to reduce them to practice. In the past month, AstraZeneca...
BioCentury | Apr 8, 2020
Deals

Zai adds second bispecific to pipeline via Regeneron deal

In Zai’s latest deal giving it local rights to a therapeutic developed in the West, the Shanghai-based biotech has partnered with Regeneron for REGN1979, a bispecific antibody that is in Phase II testing to treat...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes on a new dimension in the U.K., and the spotlight on its biopharmas to respond with countermeasures beyond physical...
BioCentury | Apr 6, 2020
Deals

Vir speeding COVID-19 mAbs into Phase II with $250M GSK investment

A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19,...
BioCentury | Apr 4, 2020
Product Development

Dealmaking in a pandemic: partnerships speeding COVID-19 countermeasures

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

BARDA’s latest push into plasma-based COVID-19 therapies includes an expanded access program for convalescent plasma and funding for Emergent’s hyperimmune program. To combat the pandemic, a pair of companies began rolling out tests, while GSK...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Mar 31, 2020
Deals

Lilly gains rights to Sitryx’s two most advanced immunometabolic programs in four-target deal

For its first pharma partnership, U.K.-based Sitryx is granting Lilly rights to its two most advanced immunometabolism programs in exchange for upfront cash and an equity investment totaling $60 million -- twice the amount of...
BioCentury | Mar 27, 2020
Product Development

Pharmas to share assets in COVID-19 consortium led by Narasimhan, Gates

Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation. Novartis AG (NYSE:NVS;...
BioCentury | Mar 21, 2020
Management Tracks

Kutok joins Epizyme as CSO; plus ADC Therapeutics, Emulate, E-Scape, MiMedx and RubrYc

Epizyme Inc. (NASDAQ:EPZM) hired Jeffery Kutok as CSO. He was EVP and CSO of Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Kutok joins the epigenetics company in the wake of its first FDA approval, for Tazverik tazemetostat to...
Items per page:
1 - 10 of 8752
BioCentury | Apr 9, 2020
Product Development

AZ’s Pangalos: what the pharma brings to COVID-19 fight, and where it turns to others

In a conversation with BioCentury, AstraZeneca’s Menelas Pangalos highlighted the technologies the pharma thinks could be difference-makers in the pandemic, and the external resources required to reduce them to practice. In the past month, AstraZeneca...
BioCentury | Apr 8, 2020
Deals

Zai adds second bispecific to pipeline via Regeneron deal

In Zai’s latest deal giving it local rights to a therapeutic developed in the West, the Shanghai-based biotech has partnered with Regeneron for REGN1979, a bispecific antibody that is in Phase II testing to treat...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes on a new dimension in the U.K., and the spotlight on its biopharmas to respond with countermeasures beyond physical...
BioCentury | Apr 6, 2020
Deals

Vir speeding COVID-19 mAbs into Phase II with $250M GSK investment

A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19,...
BioCentury | Apr 4, 2020
Product Development

Dealmaking in a pandemic: partnerships speeding COVID-19 countermeasures

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

BARDA’s latest push into plasma-based COVID-19 therapies includes an expanded access program for convalescent plasma and funding for Emergent’s hyperimmune program. To combat the pandemic, a pair of companies began rolling out tests, while GSK...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...
BioCentury | Mar 31, 2020
Deals

Lilly gains rights to Sitryx’s two most advanced immunometabolic programs in four-target deal

For its first pharma partnership, U.K.-based Sitryx is granting Lilly rights to its two most advanced immunometabolism programs in exchange for upfront cash and an equity investment totaling $60 million -- twice the amount of...
BioCentury | Mar 27, 2020
Product Development

Pharmas to share assets in COVID-19 consortium led by Narasimhan, Gates

Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation. Novartis AG (NYSE:NVS;...
BioCentury | Mar 21, 2020
Management Tracks

Kutok joins Epizyme as CSO; plus ADC Therapeutics, Emulate, E-Scape, MiMedx and RubrYc

Epizyme Inc. (NASDAQ:EPZM) hired Jeffery Kutok as CSO. He was EVP and CSO of Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Kutok joins the epigenetics company in the wake of its first FDA approval, for Tazverik tazemetostat to...
Items per page:
1 - 10 of 8752